论文部分内容阅读
目的 :观察吡格列酮对糖尿病肾病肾脏保护作用的疗效。方法 :5 0例 2型糖尿病合并肾病患者在控制饮食、运动治疗基础上 ,治疗组给予吡格列酮 15mg ,每日 1次口服 ,连续服用 3个月 ,对照组予二甲双胍 0 2 5g ,每日 3次口服 ,连续服用 3个月 ,治疗前后测定 2 4h尿蛋白、空腹血糖 (FBG )、餐后 2h血糖 ( 2hPBG)、肝功、肾功。结果 :治疗 3个月后治疗组尿蛋白明显减少 (P <0 0 1) ,对照组尿蛋白无明显变化 ,与对照组相比 ,差异有显著性 (P <0 0 5 ) ,两组治疗后FBG及 2hPBG均较治疗前明显降低 (P<0 0 1) ,治疗组与对照组相比 ,差异无显著性 (P >0 0 5 )。结论 :吡格列酮对糖尿病肾病有肾脏保护作用 ,可延缓糖尿病肾病的发生发展。
Objective: To observe the effect of pioglitazone on renal protective effect of diabetic nephropathy. Methods: Fifty patients with type 2 diabetes mellitus and nephropathy were treated with diet and exercise therapy. The treatment group was given pioglitazone 15 mg orally once daily for 3 months. The control group received metformin 0 2 5 g 3 times a day Oral, taking 3 consecutive months before and after treatment of 24h urine protein, fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG), liver function, kidney function. Results: After 3 months of treatment, urinary protein in the treatment group was significantly decreased (P <0.01), while in the control group, there was no significant change in urinary protein compared with the control group (P <0.05) After FBG and 2hPBG were significantly lower than before treatment (P <0.01), the treatment group compared with the control group, no significant difference (P> 0.05). Conclusion: Pioglitazone can protect kidney from diabetic nephropathy and delay the development of diabetic nephropathy.